GeneDx Holdings (WGS) Net Equity Issued and Repurchased (2021 - 2026)

GeneDx Holdings (WGS) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $476000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $476000.0; the TTM figure through Mar 2026 stood at $205.7 million (up 2626.05% YoY), while the FY2022 annual figure was $197.7 million, down 43.53% from the prior year.
• Net Equity Issued and Repurchased retreated to $476000.0 in Q1 2026 per WGS's latest filing, from $7.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $197.7 million in Q4 2022 and bottomed at -$197.7 million in Q3 2022.
• Historically, Net Equity Issued and Repurchased has averaged $2.0 million across 3 years, with a median of $4.0 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 156.49% in 2022 and fell as far as 156.49% in 2022.
• GeneDx Holdings' Net Equity Issued and Repurchased stood at $197.7 million in 2022, then plunged by 96.15% to $7.6 million in 2023, then slumped by 93.74% to $476000.0 in 2026.
• Business Quant data shows WGS's Net Equity Issued and Repurchased at $476000.0 in Q1 2026, $7.6 million in Q2 2023, and $197.7 million in Q4 2022.